Two pathways, two different types of hip damage

Most patients arrive at this decision with a straightforward question: 'Do I need an operation, or can an injection deal with this?' The honest answer is that the choice is rarely a matter of preference — it is primarily determined by the type of damage inside the hip joint.

The critical distinction is between a focal, contained cartilage defect and diffuse or advanced osteoarthritis. A focal defect is a discrete area of full-thickness cartilage loss with healthy tissue around it and measurable joint space still visible on plain X-ray — the kind of damage that surgical restoration can address. Diffuse or advanced osteoarthritis affects a much wider area of the joint surface; surgical reconstruction is not a realistic option in this setting, but the ChondroFiller injection — an outpatient, ultrasound-guided injectable collagen scaffold — may still be appropriate.

Femoroacetabular impingement (FAI) is the most common underlying diagnosis driving both pathways in younger and middle-aged adults, creating cartilage stress at the acetabular rim or femoral head over time.

Age and activity level also shape the conversation. Large epidemiological data from Germany suggest the average age for hip cartilage restoration surgery is around 28 years; the injectable pathway is more typically used in active adults in their 40s to mid-60s. Crucially, the ChondroFiller injection is the only option here that requires no operating theatre and no general or spinal anaesthetic — a meaningful distinction for patients with comorbidities or a strong preference to avoid surgery.

How the ChondroFiller injection works in the hip

The ChondroFiller injection is a CE-marked Class III medical device — an acellular Type I collagen scaffold that arrives as a liquid and gels in situ once placed inside the hip joint. Its mechanism is matrix-induced chondrogenesis: the collagen matrix acts as a chemotactic scaffold, recruiting the patient's own progenitor cells into the defect and guiding them towards repair without any cell harvesting or tissue transplantation. The repair tissue produced is hyaline-like — structurally supportive and distinct from the fibrocartilage that marrow-stimulation techniques generate — but it is mechanistically different from the true hyaline cartilage that procedures such as OATS or OCA can deliver.

Delivery is by ultrasound-guided injection in an outpatient clinic under local anaesthesia; the joint is not opened or dried, and the treatment requires no operating theatre.

Three measurable thresholds define candidacy for the hip:

• An ICRS Grade III or IV cartilage defect on the acetabulum or femoral head
• A lesion measuring between 2 cm² and 6 cm²
• Preserved joint space on plain X-ray — significant narrowing is a disqualifier

Hip-specific clinical evidence derives principally from a case series published by Perez-Carro in 2021, in which patients treated with the injectable scaffold showed significantly better cartilage quality at follow-up arthroscopy than untreated controls: median Outerbridge score 1.5 versus 3.0 (P=0.006) and ICRS score 1 versus 3 (P=0.002). The authors concluded that injectable ChondroFiller is a viable approach for full-thickness acetabular defects, while noting that longer-term outcome data are still needed — a caveat worth preserving for patients weighing this option.

OATS, AMIC, and OCA: what each hip surgery addresses

Three surgical options sit within the hip cartilage restoration category, each targeting a different defect size and accepting a different set of trade-offs.

OATS (osteochondral autograft transfer)

OATS harvests a cylindrical bone-and-cartilage plug from a low-load region of the patient's own joint and press-fits it directly into the defect — delivering true hyaline cartilage, the most structurally faithful repair tissue available. The technique is best suited to focal lesions typically under 2 cm²; larger areas require multiple plugs (mosaicplasty), which increases the secondary donor-site defect and technical complexity. Long-term data suggest successful outcomes in approximately 72% of patients, with failure rates rising with increasing defect size, older age, and prior surgery.

AMIC (autologous matrix-induced chondrogenesis)

AMIC extends microfracture — itself now a historical baseline rather than a modern first choice — by overlaying a bilayer Collagen I/III membrane (Chondro-Gide) on the marrow access points. The membrane stabilises the blood clot and guides fibrocartilage formation in a single arthroscopic stage. Hip-specific evidence is strongest here: in cam-type FAI patients with acetabular lesions exceeding 150 mm², AMIC produced Harris Hip Scores of 96.5 versus 93.5 for microfracture at approximately 40 months' follow-up, with fewer conversions to total hip replacement and significantly less post-operative synovitis. More patients returned to pre-injury athletic activity with AMIC. The NHS-registered REPAIR trial — comparing AMIC directly against microfracture for acetabular defects — indicates that robust long-term RCT data for hip-specific applications are still emerging.

OCA (osteochondral allograft)

Where defects exceed approximately 3–4 cm², or where structural bone-cartilage collapse has occurred, OCA transplants fresh donor tissue in a single stage, providing mature hyaline cartilage and underlying bone. Practical constraints are significant: graft availability is limited, costs are high, and integration cannot be assured.

All three procedures require an operating theatre and general or spinal anaesthesia, with any coexisting FAI anatomy typically corrected at the same time. Across all three, objective MRI assessment of repair tissue quality — using the seven-domain MERCH score, which requires 3.0T imaging — is not reliably interpretable until at least 12 months post-operatively, making realistic expectation-setting an important part of pre-operative discussion.

The factors that separate these pathways

The five decision factors only become clinically meaningful when read together — a single threshold rarely determines the pathway on its own, and their interaction is where the real decision lives.

Consider two illustrative presentations. A 48-year-old with a 3 cm² acetabular defect, preserved joint space, and comorbidities that make general anaesthesia a significant risk sits in the shared 2–6 cm² zone where both AMIC and the ChondroFiller injection are technically in range — but the absence of a safe anaesthetic window tips the balance firmly towards the outpatient injection pathway. Now place a 29-year-old cam-FAI athlete alongside: a 1.5 cm² focal defect, full joint space, no surgical fitness concerns, and a career-long interest in preserving the most durable repair tissue possible. That patient sits in OATS territory, where an autologous plug delivers true hyaline cartilage and age is on the side of long-term integration.

The five factors interact in the following sequence:

• Defect size narrows the field first: under 2 cm² points toward OATS; 2–6 cm² opens the shared zone for ChondroFiller injection or AMIC; structural collapse beyond 3–4 cm² points toward OCA.
• Damage pattern acts as the next gate: diffuse or advanced OA removes the surgical options but does not close the injection pathway.
• Joint space on X-ray is the ChondroFiller injection's own disqualifier — significant narrowing rules it out regardless of defect size.
• Surgical fitness and preference determines whether theatre-based procedures are viable; the ChondroFiller injection is the only option requiring neither operating theatre nor anaesthesia.
• Tissue quality goal shapes the long-term conversation: OATS and OCA offer true hyaline cartilage; AMIC produces fibrocartilage; ChondroFiller injection guides matrix-induced chondrogenesis toward hyaline-like repair tissue.

None of these thresholds can be confirmed without MRI, weight-bearing X-ray, and a specialist assessment — and that combination is the natural starting point for any patient working through this decision.

What outcomes and recovery look like

Recovery expectations differ substantially between the injection and surgical pathways — not because one is inherently superior, but because each procedure is attempting something different.

After the ChondroFiller injection, there is no theatre downtime. Activity modification is required in the days following the procedure, but patients are not restricted to a hospital bed or crutches for weeks. Published data show a near-zero complication rate, a reoperation rate of 3–8%, and functional improvement — measured by IKDC and modified Harris Hip Scores — averaging approximately 30 points across published series.

The surgical pathways demand more upfront, but what they require reflects what they deliver. OATS recovery involves protected weight-bearing while the donor plug integrates, along with transient discomfort at the secondary harvest site; long-term success is approximately 72%, declining with larger defects and older age. AMIC patients in cam-FAI studies returned to pre-injury athletic activity at higher rates than those who received microfracture alone, with fewer conversions to total hip replacement at roughly 40 months — meaningful results that the NHS-registered REPAIR trial will eventually supplement with formal RCT data. OCA carries the longest recovery of the four, with graft-availability timing sometimes extending the pre-operative wait before rehabilitation even begins. Where FAI anatomy is corrected at the same time — standard practice where applicable — overall recovery planning should account for that combined procedure.

MRI follow-up at 12 months is standard for surgical patients, providing the first reliable read of cartilage fill quality.

NHS access, costs, and getting assessed in Lincolnshire

Funding varies across these four pathways, and the differences are practical rather than marginal.

The ChondroFiller injection is entirely self-funded — it is not available on the NHS and is not covered by Bupa or AXA. At London Cartilage Clinic, pricing starts from approximately £3,000 per session, inclusive of consultation, ultrasound guidance, the product itself, the injection, antibiotic cover, and a six-week follow-up. OATS and AMIC can, where clinical criteria are met, be accessed via NHS referral or private medical insurance in appropriate cases. OCA is available privately and through some NHS specialist centres.

For patients in Lincolnshire and the surrounding area, the practical starting point is a hip assessment that includes MRI — ideally at 3.0 Tesla or above — to confirm defect size, cartilage grade, and joint-space status. Those three measurements are what determine which pathway, if any, is genuinely in range. Open MRI is available for patients unable to tolerate a standard closed-bore scanner.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment, with clinics in Sleaford and Grantham. Whatever pathway the imaging points toward, a confirmed diagnosis comes first: the decision framework covered in this article sets the context, but a specialist assessment is what converts it into a recommendation suited to one patient's specific hip.

1. [1] Arthroscopic Treatment of Acetabular Cartilage Lesions in Cam-Type Hip Impingement with Membrane Induced Chondrogenesis versus Microfracturing. (2016). https://doi.org/10.17265/2332-7839/2016.01.002 https://doi.org/10.17265/2332-7839/2016.01.002